scPharmaceuticals Inc.
SCPH
$4.85
$0.286.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 99.17% | 92.59% | 99.31% | 164.12% | 391.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.17% | 92.59% | 99.31% | 164.12% | 391.70% |
| Cost of Revenue | 117.87% | 94.45% | 123.63% | 206.86% | 549.72% |
| Gross Profit | 91.69% | 91.82% | 89.34% | 147.15% | 348.13% |
| SG&A Expenses | 21.24% | 22.70% | 31.60% | 50.83% | 44.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.91% | 34.39% | 33.44% | 51.18% | 46.16% |
| Operating Income | 0.95% | -11.99% | -7.12% | -22.29% | -4.98% |
| Income Before Tax | -5.47% | -39.93% | -36.44% | -124.54% | -20.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.47% | -39.93% | -36.44% | -124.54% | -20.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.47% | -39.93% | -36.44% | -124.54% | -20.74% |
| EBIT | 0.95% | -11.99% | -7.12% | -22.29% | -4.98% |
| EBITDA | 0.94% | -12.01% | -7.13% | -22.30% | -4.99% |
| EPS Basic | 23.47% | -1.55% | 1.01% | -86.96% | -19.85% |
| Normalized Basic EPS | 23.47% | -3.09% | 14.73% | -93.85% | -19.86% |
| EPS Diluted | 23.47% | -1.55% | 1.01% | -86.96% | -19.85% |
| Normalized Diluted EPS | 23.47% | -3.09% | 14.73% | -93.85% | -19.86% |
| Average Basic Shares Outstanding | 37.80% | 37.80% | 37.84% | 20.12% | 0.75% |
| Average Diluted Shares Outstanding | 37.80% | 37.80% | 37.84% | 20.12% | 0.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |